NCT03985371

Brief Summary

The objective of this study is to collect preliminary efficacy and safety data on the use of EDTA EYE Drops (EED) on subjects during an episode of band keratopathy (BK).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for early_phase_1

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 13, 2019

Completed
1 year until next milestone

Study Start

First participant enrolled

June 29, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

January 5, 2022

Status Verified

January 1, 2022

Enrollment Period

1.3 years

First QC Date

June 7, 2019

Last Update Submit

January 4, 2022

Conditions

Keywords

Band Keratopathy

Outcome Measures

Primary Outcomes (3)

  • Changes of the Cornea

    Photographs will be full, direct views taken with a Zeiss model 450 plus split lamp camera.

    Days 1, 120 and 180 after the start of the study.

  • Change in Snellen Visual Acuity

    The Snellen Chart is used to assess visual acuity by asking subjects to read as many of the 11 lines of block letters as they are able.

    Days 1, 7, 60, 120 and 180 after the start of the study.

  • Change in the Symptoms Associated with Band Keratopathy

    Evaluation of pain, as rated by the subject on a visual analog scale, will be the primary symptom assessed throughout this study.

    Days 1, 7, 60, 180, 270, 360, 540 and 720 after the start of the study.

Study Arms (1)

Drops Used

EXPERIMENTAL
Drug: EDTA Eye Drops

Interventions

One drop in the Band Keratopathy affected eye only, two times per day for six months.

Drops Used

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Understand the requirements of the study and provide informed consent prior to undergoing any study-related procedures
  • Be between the ages of 40 and 80 years old, inclusive
  • Have a documented BK diagnosis
  • Be willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of symptoms

You may not qualify if:

  • Use other therapies for BK including amniotic membrane or conjunctival grafts.
  • Have other co-morbidities that may confound the safety and efficacy measurements for this study.
  • Have participated in any other clinical trial within 30 days prior to enrollment.
  • Have any condition, abnormality or situation at Baseline that in the opinion of the Principal Investigator may preclude the subject's ability to comply with study requirements, including completion of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rochester

Rochester, New York, 14642, United States

Location

MeSH Terms

Conditions

Corneal Dystrophy, Band-Shaped

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 7, 2019

First Posted

June 13, 2019

Study Start

June 29, 2020

Primary Completion

September 30, 2021

Study Completion

September 30, 2021

Last Updated

January 5, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations